FTC wants_more_time_to_review SNY-PRVB deal: https://www.globenewswire.com/news-release/2023/04/10/2643960/0/en/Press-Release-Sanofi-announces-withdrawal-and-refiling-of-Premerger-Notification-and-Report-Form-under-the-HSR-Act-and-extension-of-tender-offer-to-acquire-Provention-Bio-Inc.html I don’t see any deal-killing issues here; however, the FTC is taking nothing for granted when it comes to drug/biotech mergers.